The Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) drugs in development market research report provides comprehensive information on the therapeutics under development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and features dormant and discontinued products.
GlobalData tracks 43 drugs in development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) by 33 companies/universities/institutes. The top development phase for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) is phase ii with 24 drugs in that stage. The Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline has 43 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline products market are: Novartis, Incyte and Chia Tai Tianqing Pharmaceutical Group.
The key targets in the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline products market include Tyrosine Protein Kinase JAK2, Tyrosine Protein Kinase JAK1, and Receptor Type Tyrosine Protein Kinase FLT3.
The key mechanisms of action in the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline product include Tyrosine Protein Kinase JAK2 Inhibitor with ten drugs in Phase III. The Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline products include four routes of administration with the top ROA being Oral and six key molecule types in the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline products market including Small Molecule, and Monoclonal Antibody.
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) overview
Post-essential thrombocythemia myelofibrosis (post-ET MF) is a rare, chronic blood disorder characterized by the progression of essential thrombocythemia (ET), a type of myeloproliferative neoplasm (MPN), to myelofibrosis (MF). It represents an advanced stage in the continuum of MPNs, involving abnormal production and functioning of blood cells in the bone marrow. Essential thrombocythemia is characterized by the overproduction of platelets (thrombocytes) leading to an increased risk of blood clots. Over time, a subset of individuals with ET may progress to myelofibrosis, a condition where the bone marrow becomes fibrotic (scarred), leading to impaired production of blood cells. The symptoms of post-ET MF can vary widely and include fatigue, weakness, and shortness of breath due to anemia; enlargement of the spleen, leading to abdominal discomfort or pain; bone pain, especially in the ribs and back; easy bruising, bleeding, or prolonged bleeding time due to abnormal platelet function; and night sweats, weight loss, or fever.
For a complete picture of Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
